Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Diabetes Care 30: 1562-1566
Based on the Wegovy Summary of Product Characteristics (SmPC), no clinically relevant interactions are expected between semaglutide and the typical ingredients found in cold and flu remedies
You should never try to power through severe side effects
Other GLP-1 Agonists Based on published clinical trial data, here's how retatrutide's side effect profile compares: Key observations: Retatrutide shows similar or lower GI side effect rates compared to maximum doses of competing peptides The glucagon receptor component doesn't appear to significantly increase side effect burden Discontinuation rates are comparable across all three agents Heart rate effects may be slightly lower with retatrutide The takeaway: retatrutide's trial-reported safety profile is at or below semaglutide and high-dose tirzepatide on the metrics that matter nausea, diarrhea, vomiting, discontinuation
Mounjaro (tirzepatide), which is a GIP/GLP-1 agonist, and Victoza (liraglutide), a GLP-1 agonist, are used to treat Type 2 diabetes, while Zepbound (tirzepatide) and Saxenda (liraglutide) are used for weight loss
US$ 28.47
US$ 21.72
US$ 29.27
US$ 27.73
US$ 25.63
